A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.

Front Immunol · 2024 · PMC11190074 · PMID 38911861

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In fact, a recent paper published in pediatric and adolescent MS patients treated with fingolimod identified different haplotypes that showed a trend towards a more favorable clinical course ( 14 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.